Global stocks remain constructive as semis sell off â HSBCâs Max Kettner
HSBCâs Max Kettner sees global equities resilient amid tech weakness, with semis signaling buys and Europe/Japan opportunities.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.

HSBCâs Max Kettner sees global equities resilient amid tech weakness, with semis signaling buys and Europe/Japan opportunities.
Global stocks remain constructive as semis sell off â HSBCâs Max Kettner | Seeking Alpha
Save
Play
(
3min
)
Comments
HSBC's chief multi-asset strategist, Max Kettner, remains âreally constructiveâ on global equities despite recent technology sector weakness, arguing that semiconductor (
IGV
), (
XSW
) positioning is already flashing buy signals.
In an interview with CNBC, Kettner characterized the pullback as a positioning-driven correction
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
Why is HSBC constructive on global equities despite tech weakness?
HSBC sees the tech selloff as positioning-driven, notes overall market resilience, and believes minimal recession risk and stable Fed policy underpin a positive outlook.
What is the rationale for shifting from emerging markets to European equities?
HSBC shifted due to momentum liquidation pressures impacting emerging Asia and sees European equities as closely tracking the S&P 500, benefiting from broader market leadership.
Why does HSBC view Japanese equities as a buy despite regional selloffs?
HSBC attributes Asian selloffs to forced liquidation, not fundamentals, and highlights Japan's support from fiscal initiatives, strong bank earnings, and better corporate governance.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Domino's Pizza Q2 2026 Earnings Preview: Same-Store Sales, Cost Control, and Growth Outlook
A deep dive into Domino's Pizza's Q2 2026 earnings, covering U.S. same-store sales trends, international expansion, ingredient and labor cost pressures, digital delivery advantages, and valuation sentiment.

Novartis wins full FDA approval for Fabhalta in IgAN (NVS:NYSE)
Novartis (NVS) wins full FDA approval for the kidney disease drug, Fabhalta, to slow kidney function decline in adults with primary IgA nephropathy. Read more here.

Q2 earnings: Top and bottom Quant-rated materials stocks (XLB:NYSEARCA)
Track Q2 earnings for materials stocks: XLB beats S&P 500 YTD.

AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE)
AbbVie (ABBV) unit Allergan wins EU approval for the Boey anti-wrinkle injectable for temporary improvement of frown lines across 30 European countries. Read more here.
